trending Market Intelligence /marketintelligence/en/news-insights/trending/71xBOnkLB6AL88ag433Efg2 content esgSubNav
In This List

Lonza secures long-term agreement to manufacture kidney drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Lonza secures long-term agreement to manufacture kidney drug

Lonza Group Ltd. nabbed a contract to manufacture Voclosporin on Aurinia Pharmaceuticals Inc.'s behalf.

Lonza Group will supply the patent-protected investigational drug for phase 3 clinical trial to determine whether it can be used to treat lupus nephritis, an inflammation of the kidneys.

The agreement also gives Lonza exclusivity to supply the drug for up to 20 years.